TY - JOUR
AB - References 1 Bellet S . Clinical Disorders of the Heart Beat. Philadelphia: Lea & Febiger; 1971. 2 Prystowsky EN , Katz AM. Atrial fibrillation. Topol ES. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven; 1998. p. 1827–1861 3 Levy S , Breithardt G, Campbell RW. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J . 1998 ; 19 : 1294 –1320 4 Jais P , Haissaguerre M, Shah DC. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation . 1997 ; 95 : 572 –576 5 Allessie MA , Konings KT, Kirchhof CJ. Mapping of atrial fibrillation. Olsson SB, Allessie MA, Campbell RW. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk: Futura Publ; 1994. p. 37–49 6 Levy S , Novella P, Ricard P, Paganelli F. Paroxysmal atrial fibrillation: a need for classification. J Cardiovasc Electrophysiol . 1995 ; 6 : 69 –74 7 Sopher SM , Camm AJ. Therapy for atrial fibrillation: control of the ventricular response and prevention of recurrence. Coron Artery Dis . 1995 ; 6 : 106 –114 8 Levy S . Classification system of atrial fibrillation. Curr Opin Cardiol . 2000 ; 15 : 54 –57 9 Gallagher MM , Camm J. Classification of atrial fibrillation. Am J Cardiol . 1998 ; 82 : 18N –28N 10 Kopecky SL , Gersh BJ, McGoon MD. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med . 1987 ; 317 : 669 –674 11 Feinberg WM , Cornell ES, Nightingale SD. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke . 1997 ; 28 : 1101 –1106 12 Ostranderld JR , Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation . 1965 ; 31 : 888 –898 13 Flegel KM , Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation [published erratum appears in Lancet 1987; 1: 878]. Lancet . 1987 ; 1 : 526 –529 14 Wolf PA , Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke . 1991 ; 22 : 983 –988 15 Furberg CD , Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol . 1994 ; 74 : 236 –241 16 Kannel WB , Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J . 1983 ; 106 : 389 –396 17 Psaty BM , Manolio TA, Kuller LH. Incidence of and risk factors for atrial fibrillation in older adults. Circulation . 1997 ; 96 : 2455 –2461 18 Go AS , Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA . 2001 ; 285 : 2370 –2375 19 Evans W , Swann P. Lone auricular fibrillation. Br Heart J . 1954 ; 16 : 189 –194 20 Brand FN , Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA . 1985 ; 254 : 3449 –3453 21 Levy S , Maarek M, Coumel P. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation . 1999 ; 99 : 3028 –3035 22 Murgatroyd FD , Gibson SM, Baiyan X. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation . 1999 ; 99 : 2765 –2770 23 Wolf PA , Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med . 1987 ; 147 : 1561 –1564 24 Krahn AD , Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med . 1995 ; 98 : 476 –484 25 Benjamin EJ , Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA . 1994 ; 271 : 840 –844 26 Pedersen OD , Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation . 1999 ; 100 : 376 –380 27 Crijns HJ , Tjeerdsma G, De Kam PJ. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J . 2000 ; 21 : 1238 –1245 28 Arch Intern Med . 1994 ; 154 : 1449 –1457 29 Hart RG , Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med . 1999 ; 131 : 688 –695 30 Feinberg WM , Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med . 1990 ; 150 : 2340 –2344 31 Kempster PA , Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke . 1988 ; 19 : 955 –957 32 Circulation . 1991 ; 84 : 527 –539 33 Petersen P , Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke . 1987 ; 18 : 1098 –1100 34 Wolf PA , Dawber TR, Thomas HE Jr., Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology . 1978 ; 28 : 973 –977 35 Carson PE , Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation . 1993 ; 87 : VI-102 –10 36 Dries DL , Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol . 1998 ; 32 : 695 –703 37 Feinberg WM , Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med . 1995 ; 155 : 469 –473 38 Bharti S , Lev M. Histology of the normal and diseased atrium. Falk RH, Podrid PJ. Atrial Fibrillation: Mechanism and Management. New York: Raven Press; 1992. p. 15–39 39 Guiraudon CM , Ernst NM, Yee R, Lein GJ. The pathology of drug resistant lone atrial fibrillation in eleven surgically treated patients. Kingma JH, Van Hernel NM, Lie KI. Atrial Fibrillation: A Treatable Disease?. Dordrecht: Kluwer Academic Publ; 1992. p. 41–57 40 Frustaci A , Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation . 1997 ; 96 : 1180 –1184 41 Dittrich HC , Pearce LA, Asinger RW. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. Am Heart J . 1999 ; 137 : 494 –499 42 Li D , Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation . 1999 ; 100 : 87 –95 43 Maixent JM , Paganelli F, Scaglione J, Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol . 1998 ; 9 : 612 –617 44 Moe GK , Abildskov JA. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. Am Heart J . 1959 ; 58 : 59 –70 45 Rensma PL , Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res . 1988 ; 62 : 395 –410 46 Scherf D , Romano FJ, Terranova R. Experimental studies on auricular flutter and auricular fibrillation. Am Heart J . 1948 ; 36 : 241 47 Scherf D , Schaffer AI, Blumfeld S. Mechanism of flutter and fibrillation. Arch Intern Med . 1953 ; 91 : 241 –251 48 Haissaguerre M , Jais P, Shah DC. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med . 1998 ; 339 : 659 –666 49 Chen SA , Tai CT, Yu WC. Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol . 1999 ; 10 : 328 –335 50 Spach MS , Barr RC, Jewett PH. Spread of excitation from the atrium into thoracic veins in human beings and dogs. Am J Cardiol . 1972 ; 30 : 844 –854 51 Nathan H , Eliakim M. The junction between the left atrium and the pulmonary veins: an anatomic study of human hearts. Circulation . 1966 ; 34 : 412 –422 52 Zipes DP , Knope RF. Electrical properties of the thoracic veins. Am J Cardiol . 1972 ; 29 : 372 –376 53 Cheung DW . Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol (Lond) . 1981 ; 314 : 445 –456 54 Cheung DW . Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia. Nature . 1981 ; 294 : 582 –584 55 Paes DA , Bohm CM, de Paula CM, Paes DC. The cardiac muscle in the pulmonary vein of the rat: a morphological and electrophysiological study. J Morphol . 1975 ; 145 : 409 –433 56 Moe GK , Abildskov JA. Observations on the ventricular dysrhythmia associated with atrial fibrillation in the dog heart. Circ Res . 1964 ; 4 : 447 –460 57 Allessie MA , Lammers WJ, Bonke FI, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. Zipes DP, Jalife J. Cardiac Electrophysiology and Arrhythmias. New York: Grune & Stratton; 1985. p. 265–276 58 Cox JL , Canavan TE, Schuessler RB. The surgical treatment of atrial fibrillation, II: intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg . 1991 ; 101 : 406 –426 59 Konings KT , Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation . 1994 ; 89 : 1665 –1680 60 Skanes AC , Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. Circulation . 1998 ; 98 : 1236 –1248 61 Kumagai K , Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: insights into the mechanism of its maintenance. Circulation . 1997 ; 95 : 511 –521 62 Gray RA , Pertsov AM, Jalife J. Incomplete reentry and epicardial breakthrough patterns during atrial fibrillation in the sheep heart. Circulation . 1996 ; 94 : 2649 –2661 63 Dorostkar PC , Cheng J, Scheinman MM. Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease. Pacing Clin Electrophysiol . 1998 ; 21 : 1810 –1819 64 Konings, KTS, Mapping of electrically induced atrial fibrillation in humans [thesis], University of Limberg, Maastricht, Netherlands, 1999 65 Ricard P , Levy S, Trigano J. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol . 1997 ; 79 : 815 –816 66 Wijffels MC , Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation . 1995 ; 92 : 1954 –1968 67 Attuel P , Pellerin D, Gaston J. Latent atrial vulnerability: new means of electrophysiologic investigations in paroxysmal atrial arrhythmias. Attuel P, Coumel P, Janse MJ. The Atrium in Health and Disease. Mount Kisco: Futura Publ; 1989. p. 81–94 68 Franz MR , Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol . 1997 ; 30 : 1785 –1792 69 Olsson SB , Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand . 1971 ; 190 : 381 –387 70 Yue L , Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res . 1997 ; 81 : 512 –525 71 Fareh S , Benardeau A, Thibault B, Nattel S. The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation . 1999 ; 100 : 2191 –2197 72 Tieleman RG , De Langen C, Van Gelder IC. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation . 1997 ; 95 : 1945 –1953 73 Daoud EG , Marcovitz P, Knight BP. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation . 1999 ; 99 : 3024 –3027 74 Elvan A , Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling. Circulation . 1996 ; 94 : 2953 –2960 75 Manios EG , Kanoupakis EM, Mavrakis HE, Kallergis EM, Dermitzaki DN, Vardas PE. Sinus pacemaker function after cardioversion of chronic atrial fibrillation: is sinus node remodeling related with recurrence? J Cardiovasc Electrophysiol . 2001 ; 12 : 800 –806 76 White CW , Kerber RE, Weiss HR, Marcus ML. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res . 1982 ; 51 : 205 –215 77 Edwards BS , Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res . 1988 ; 62 : 191 –195 78 Spach MS . Nonuniform anisotropic cellular coupling as a basis for reentrant arrhythmias. DiMarco JP, Prystowsky EN. Atrial Arrhythmias: State of the Art. Armonk: Futura Publ; 1995. p. 123–147 79 Misier AR , Opthof T, van Hemel NM. Increased dispersion of ‘refractoriness’ in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol . 1992 ; 19 : 1531 –1535 80 Cosio FG , Palacios J, Vidal JM, Cocina EG, Gomez-Sanchez MA, Tamargo L. Electrophysiologic studies in atrial fibrillation: slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol . 1983 ; 51 : 122 –130 81 Cox JL , Boineau JP, Schuessler RB, Jaquiss RD, Lappas DG. Modification of the maze procedure for atrial flutter and atrial fibrillation, I: rationale and surgical results. J Thorac Cardiovasc Surg . 1995 ; 110 : 473 –484 82 Cox JL , Jaquiss RD, Schuessler RB, Boineau JP. Modification of the maze procedure for atrial flutter and atrial fibrillation, II: surgical technique of the maze III procedure. J Thorac Cardiovasc Surg . 1995 ; 110 : 485 –495 83 Elvan A , Pride HP, Eble JN, Zipes DP. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation . 1995 ; 91 : 2235 –2244 84 Klingenheben T , Gronefeld G, Li YG, Hohnloser SH. Heart rate variability to assess changes in cardiac vagal modulation prior to the onset of paroxysmal atrial fibrillation in patients with and without structural heart disease. ANE . 1999 ; 4 : 19 –26 85 Chen SA , Hsieh MH, Tai CT. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation . 1999 ; 100 : 1879 –1886 86 Coumel P , Attuel P, Leclercq JF, Friocourt P. Atrial arrhythmias of vagal or catecholaminergic origin: comparative effects of beta-blocker treatment and the escape phenomenon [in French]. Arch Mal Coeur Vaiss . 1982 ; 75 : 373 –387 87 Prystowsky EN . Tachycardia-induced tachycardia: a mechanism of initiation of atrial fibrillation. DiMarco JP, Prystowsky EN. Atrial Arrhythmias: State of the Art. Armonk: Futura Publ; 1995. p. 123–149 88 Hurwitz JL , German LD, Packer DL. Occurrence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia due to atrioventricular nodal reentry. Pacing Clin Electrophysiol . 1990 ; 13 : 705 –710 89 Brugada J , Mont L, Matas M, Navarro-Lopez F. Atrial fibrillation induced by atrioventricular nodal reentrant tachycardia. Am J Cardiol . 1997 ; 79 : 681 –682 90 Prystowsky EN . Atrioventricular node reentry: physiology and radiofrequency ablation. Pacing Clin Electrophysiol . 1997 ; 20 : 552 –571 91 Mazgalev T , Dreifus LS, Bianchi J, Michelson EL. Atrioventricular nodal conduction during atrial fibrillation in rabbit heart. Am J Physiol . 1982 ; 243 : H754 –60 92 Page RL , Wharton JM, Prystowsky EN. Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. Am J Cardiol . 1996 ; 77 : 260 –265 93 Lagendorf R , Pick AL, Katz LN. Ventricular response in atrial fibrillation: role of concealed conduction in the AV junction. Circulation . 1965 ; 32 : 69 –75 94 Page RL , Tang AS, Prystowsky EN. Effect of continuous enhanced vagal tone on atrioventricular nodal and sinoatrial nodal function in humans. Circ Res . 1991 ; 68 : 1614 –1620 95 Van Den Berg MP , Crijns HJ, Haaksma J, Brouwer J, Lie KI. Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation. Clin Sci (Colch) . 1994 ; 86 : 531 –535 96 Gouaux JL , Ashman R. Auricular fibrillation with aberration simulating ventricular paroxysmal tachycardia. Am Heart J . 1947 ; 34 : 366 –373 97 Klein GJ , Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med . 1979 ; 301 : 1080 –1085 98 Chen PS , Prystowsky EN. Role of concealed and supernormal conductions during atrial fibrillation in the preexcitation syndrome. Am J Cardiol . 1991 ; 68 : 1329 –1334 99 Dreifus LS , Haiat R, Watanabe Y, Arriaga J, Reitman N. Ventricular fibrillation: a possible mechanism of sudden death in patients and Wolff-Parkinson-White syndrome. Circulation . 1971 ; 43 : 520 –527 100 Prystowsky EN , Benson DW Jr., Fuster V. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation . 1996 ; 93 : 1262 –1277 101 Naito M , David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J . 1983 ; 106 : 284 –291 102 Clark DM , Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol . 1997 ; 30 : 1039 –1045 103 Brookes CI , White PA, Staples M. Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. Circulation . 1998 ; 98 : 1762 –1768 104 Upshaw CB Jr . Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med . 1997 ; 157 : 1070 –1076 105 Van Den Berg MP , Tuinenburg AE, van Veldhuisen DJ, De Kam PJ, Crijns HJ. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. Int J Cardiol . 1998 ; 63 : 63 –70 106 Morillo CA , Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation . 1995 ; 91 : 1588 –1595 107 Ausma J , Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation . 1997 ; 96 : 3157 –3163 108 Sanfilippo AJ , Abascal VM, Sheehan M. Atrial enlargement as a consequence of atrial fibrillation: a prospective echocardiographic study. Circulation . 1990 ; 82 : 792 –797 109 Gosselink AT , Crijns HJ, Hamer HP, Hillege H, Lie KI. Changes in left and right atrial size after cardioversion of atrial fibrillation: role of mitral valve disease. J Am Coll Cardiol . 1993 ; 22 : 1666 –1672 110 Mitusch R , Garbe M, Schmucker G, Schwabe K, Stierle U, Sheikhzadeh A. Relation of left atrial appendage function to the duration and reversibility of nonvalvular atrial fibrillation. Am J Cardiol . 1995 ; 75 : 944 –947 111 Manning WJ , Silverman DI, Katz SE. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol . 1994 ; 23 : 1535 –1540 112 Packer DL , Bardy GH, Worley SJ. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol . 1986 ; 57 : 563 –570 113 Grogan M , Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol . 1992 ; 69 : 1570 –1573 114 Philips E , Levine SA. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med . 1949 ; 7 : 478 –489 115 Kieny JR , Sacrez A, Facello A. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J . 1992 ; 13 : 1290 –1295 116 Shinbane JS , Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol . 1997 ; 29 : 709 –715 117 Halperin JL , Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke . 1988 ; 19 : 937 –941 118 Bogousslavsky J , Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology . 1990 ; 40 : 1046 –1050 119 Miller VT , Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology . 1993 ; 43 : 32 –36 120 Kanter MC , Tegeler CH, Pearce LA. Carotid stenosis in patients with atrial fibrillation: prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med . 1994 ; 154 : 1372 –1377 121 Aschenberg W , Schluter M, Kremer P, Schroder E, Siglow V, Bleifeld W. Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus. J Am Coll Cardiol . 1986 ; 7 : 163 –166 122 Mugge A , Kuhn H, Nikutta P, Grote J, Lopez JA, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol . 1994 ; 23 : 599 –607 123 Chimowitz MI , DeGeorgia MA, Poole RM, Hepner A, Armstrong WM. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke . 1993 ; 24 : 1015 –1019 124 Manning WJ , Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol . 1989 ; 13 : 617 –623 125 Grimm RA , Stewart WJ, Maloney JD. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol . 1993 ; 22 : 1359 –1366 126 Fatkin D , Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol . 1994 ; 23 : 961 –969 127 Daniel WG , Nellessen U, Schroder E. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol . 1988 ; 11 : 1204 –1211 128 Hwang JJ , Ko FN, Li YH. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation. Cardiology . 1994 ; 85 : 69 –75 129 Pop GA , Meeder HJ, Roelandt JR. Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events. Eur Heart J . 1994 ; 15 : 1545 –1551 130 Li YH , Lai LP, Shyu KG, Hwang JJ, Kuan P, Lien WP. Clinical implications of left atrial appendage flow patterns in nonrheumatic atrial fibrillation. Chest . 1994 ; 105 : 748 –752 131 Mitusch R , Lange V, Stierle U, Maurer B, Sheikhzadeh A. Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation. Int J Card Imaging . 1995 ; 11 : 27 –34 132 Black IW , Chesterman CN, Hopkins AP, Lee LC, Chong BH, Walsh WF. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol . 1993 ; 21 : 451 –457 133 Stoddard MF , Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol . 1995 ; 25 : 452 –459 134 Manning WJ , Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med . 1995 ; 155 : 2193 –2198 135 Gustafsson C , Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke . 1990 ; 21 : 47 –51 136 Heppell RM , Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart . 1997 ; 77 : 407 –411 137 Lip GY . Hypercoagulability and haemodynamic abnormalities in atrial fibrillation (comment). Heart . 1997 ; 77 : 395 –396 138 Al-Saady NM , Davies MJ, Luddington LA. Tissue factor and von Willebrand factor expressions increased in the atrial tissue of the fibrillating atrium (Abstr). Circulation . 2000 ; 100 : I-285 139 Mitusch R . Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost . 1996 ; 75 : 219 –223 140 Lip GY , Lip PL, Zarifis J. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation . 1996 ; 94 : 425 –431 141 Lip GY , Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J . 1996 ; 131 : 724 –730 142 Asakura H , Hifumi S, Jokaji H. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis . 1992 ; 3 : 469 –473 143 Sohara H , Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol . 1997 ; 29 : 106 –112 144 Oltrona L , Broccolino M, Merlini PA, Spinola A, Pezzano A, Mannucci PM. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation . 1997 ; 95 : 2003 –2006 145 Yamamoto K , Ikeda U, Seino Y. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol . 1995 ; 25 : 107 –112 146 Peverill RE , Harper RW, Gelman J, Gan TE, Harris G, Smolich JJ. Determinants of increased regional left atrial coagulation activity in patients with mitral stenosis. Circulation . 1996 ; 94 : 331 –339 147 Fukazawa H , Yamamoto K, Ikeda U, Shimada K. Effect of mitral regurgitation on coagulation activity in atrial fibrillation. Am J Cardiol . 1998 ; 81 : 93 –96 148 Asinger RW , Koehler J, Pearce LA. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, II: dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation BRACESPAF-IIIBRACEO study). J Am Soc Echocardiogr . 1999 ; 12 : 1088 –1096 149 Goldman ME , Pearce LA, Hartz RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation, I: reduced flow velocity in the left atrial appendage. J Am Soc Echocardiogr . 2000 ; 12 : 1080 –1087 150 Blackshear JL , Pearce LA, Hart RG. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke . 1999 ; 30 : 834 –840 151 Collins LJ , Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation: reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation . 1995 ; 92 : 160 –163 152 Hwang JJ , Shyu KG, Hsu KL, Chen JJ, Kuan P, Lien WP. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast formation, but not against systemic embolism. Chest . 1994 ; 106 : 8 –12 153 Movsowitz C , Movsowitz HD, Jacobs LE, Meyerowitz CB, Podolsky LA, Kotler MN. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography. J Am Soc Echocardiogr . 1993 ; 6 : 107 –114 154 Blackshear JL , Pearce LA, Asinger RW. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Am J Cardiol . 1993 ; 72 : 840 –843 155 Hart RG , Pearce LA, Miller VT. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation studies. Cerebrovasc Dis . 2000 ; 10 : 39 –43 156 Zabalgoitia M , Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol . 1998 ; 31 : 1622 –1626 157 Dreslinski GR , Frohlich ED, Dunn FG, Messerli FH, Suarez DH, Reisin E. Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. Am J Cardiol . 1981 ; 47 : 1087 –1090 158 Frohlich ED , Apstein C, Chobanian AV. The heart in hypertension [published erratum appears in N Engl J Med 1992; 327: 1768]. N Engl J Med . 1992 ; 327 : 998 –1008 159 Schmieder RE , Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA . 1996 ; 275 : 1507 –1513 160 Cushman M , Psaty BM, Macy E. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol . 1996 ; 16 : 1163 –1169 161 Hursting MJ , Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem . 1993 ; 39 : 683 –686 162 Lowe GD , Rumley A, Woodward M. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey, I: illustrative reference ranges by age, sex and hormone use. Br J Haematol . 1997 ; 97 : 775 –784 163 Hart RG , Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke . 1999 ; 30 : 1223 –1229 164 J Stroke Cerebrovasc Dis . 1993 ; 3 : 181 –188 165 Ann Intern Med . 1992 ; 116 : 1 –5 166 Ann Intern Med . 1992 ; 116 : 6 –12 167 Arch Intern Med . 1998 ; 158 : 1316 –1320 168 Yoshida M , Nakamura Y, Higashikawa M, Kinoshita M. Predictors of ischemic stroke in non-rheumatic atrial fibrillation. Int J Cardiol . 1996 ; 56 : 61 –70 169 Stollberger C , Chnupa P, Kronik G. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med . 1998 ; 128 : 630 –638 170 Tsai LM , Lin LJ, Teng JK, Chen JH. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol . 1997 ; 58 : 163 –169 171 Rathore SS , Berger AK, Weinfurt KP. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation . 2000 ; 101 : 969 –974 172 Brugada R , Tapscott T, Czernuszewicz GZ. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med . 1997 ; 336 : 905 –911 173 Coumel, P, Neural aspects of paroxysmal atrial fibrillation, Falk, RHPodrid, PJ, Atrial Fibrillation: Mechanisms and Management, New York, Raven Press, 1992, 109, 25 174 Ganiats TG , Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation: New York Heart Association. Am Heart J . 1998 ; 135 : 819 –824 175 Hamer ME , Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol . 1994 ; 74 : 826 –829 176 Dorian P , Paquette M, Newman D, Green MS, Talajic M, Roy D. Quality of life improves following treatment in the Canadian Trial of Atrial Fibrillation (Abstr). Circulation . 1999 ; 100 : I-502 177 Greenbaum RA . Oral dofetilide improves quality of life: an EMERALD substudy (Abstr). Circulation . 1999 ; 100 : I-493 178 Am J Cardiol . 1997 ; 79 : 1198 –1202 179 Hohnloser SH , Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet . 2000 ; 356 : 1789 –1794 180 Marshall HJ , Harris ZI, Griffith MJ, Holder RL, Gammage MD. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation . 1999 ; 99 : 1587 –1592 181 Natale A , Zimerman L, Tomassoni G. AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance. Pacing Clin Electrophysiol . 1999 ; 22 : 1634 –1639 182 Brignole M , Menozzi C, Gianfranchi L. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation . 1998 ; 98 : 953 –960 183 Kay GN , Ellenbogen KA, Giudici M. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol . 1998 ; 2 : 121 –135 184 Marshall HJ , Harris ZI, Griffith MJ, Gammage MD. Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation. Heart . 1998 ; 79 : 543 –547 185 Brignole M , Gianfranchi L, Menozzi C. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation . 1997 ; 96 : 2617 –2624 186 Bubien RS , Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation . 1996 ; 94 : 1585 –1591 187 Wood MA , Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation . 2000 ; 101 : 1138 –1144 188 Anselme F , Saoudi N, Poty H, Douillet R, Cribier A. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Circulation . 1999 ; 99 : 534 –540 189 Lee SH , Tai CT, Yu WC. Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. Am J Cardiol . 1999 ; 84 : 278 –283 190 Gage BF , Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med . 1996 ; 156 : 1829 –1836 191 Protheroe J , Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ . 2000 ; 320 : 1380 –1384 192 Kerr CR , Boone J, Connolly SJ. The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. Am J Cardiol . 1998 ; 82 : 82N –5N 193 Kannel WB , Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med . 1982 ; 306 : 1018 –1022 194 Cuddy TE , Connolly SJ. Atrial fibrillation and atrial flutter. Can J Cardiol . 1996 ; 12 : 9A –11A 195 Manning WJ , Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med . 1993 ; 328 : 750 –755 196 Krahn AD , Klein GJ, Kerr CR. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med . 1996 ; 156 : 2221 –2224 197 Gillis AM , Klein GJ, MacDonald RG. Investigation of the patient with atrial fibrillation. Can J Cardiol . 1996 ; 12 : 12A –13A 198 Seward JB , Khandheria BK, Freeman WK. Multiplane transesophageal echocardiography: image orientation, examination technique, anatomic correlations, and clinical applications. Mayo Clin Proc . 1993 ; 68 : 523 –551 199 Agmon Y , Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol . 1999 ; 34 : 1867 –1877 200 Pearson AC , Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol . 1991 ; 17 : 66 –72 201 Klein AL , Grimm RA, Murray RD. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med . 2001 ; 344 : 1411 –1420 202 Leung DY , Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol . 1994 ; 24 : 755 –762 203 Manning WJ , Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol . 1995 ; 25 : 1354 –1361 204 Klein AL , Grimm RA, Black IW. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study: a randomized, controlled trial: Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Intern Med . 1997 ; 126 : 200 –209 205 Black IW , Fatkin D, Sagar KB. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: a multicenter study. Circulation . 1994 ; 89 : 2509 –2513 206 Borgeat A , Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol . 1986 ; 58 : 496 –498 207 Suttorp MJ , Kingma JH, Lie AH, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol . 1989 ; 63 : 693 –696 208 Suttorp MJ , Kingma JH, Jessurun ER, Lie AH, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol . 1990 ; 16 : 1722 –1727 209 Platia EV , Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol . 1989 ; 63 : 925 –929 210 Capucci A , Lenzi T, Boriani G. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol . 1992 ; 70 : 69 –72 211 Capucci A , Boriani G, Rubino I, Della CS, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol . 1994 ; 43 : 305 –313 212 Azpitarte J , Alvarez M, Baun O. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation: results of a randomized, double-blind, controlled study. Eur Heart J . 1997 ; 18 : 1649 –1654 213 Kochiadakis GE , Igoumenidis NE, Solomou MC, Kaleboubas MD, Chlouverakis GI, Vardas PE. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol . 1999 ; 83 : 58 –61 214 Galve E , Rius T, Ballester R. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol . 1996 ; 27 : 1079 –1082 215 Falk RH , Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol . 1997 ; 29 : 385 –390 216 Norgaard BL , Wachtell K, Christensen PD. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J . 1999 ; 137 : 1062 –1069 217 Peuhkurinen K , Niemela M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol . 2000 ; 85 : 462 –465 218 Kerin NZ , Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med . 1996 ; 156 : 49 –53 219 Zehender M , Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol . 1992 ; 19 : 1054 –1059 220 Donovan KD , Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol . 1995 ; 75 : 693 –697 221 Bertini G , Conti A, Fradella G. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med . 1990 ; 8 : 15 –20 222 Hou ZY , Chang MS, Chen CY. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J . 1995 ; 16 : 521 –528 223 Opolski G , Stanislawska J, Gorecki A, Swiecicka G, Torbicki A, Kraska T. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Clin Cardiol . 1997 ; 20 : 337 –340 224 Noc M , Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol . 1990 ; 65 : 679 –680 225 Tieleman RG , Gosselink AT, Crijns HJ. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol . 1997 ; 79 : 53 –57 226 Sedgwick ML , Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol . 1995 ; 49 : 159 –166 227 Torp-Pedersen C , Moller M, Bloch-Thomsen PE. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med . 1999 ; 341 : 857 –865 228 Lindeboom JE , Kingma JH, Crijns HJ, Dunselman PH. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am J Cardiol . 2000 ; 85 : 1031 –1033 229 Botto GL , Bonini W, Broffoni T. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol . 1994 ; 17 : 2114 –2117 230 Botto GL , Capucci A, Bonini W. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol . 1997 ; 58 : 55 –61 231 Donovan KD , Dobb GJ, Coombs LJ. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol . 1991 ; 67 : 137 –141 232 Barranco F , Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med . 1994 ; 20 : 42 –44 233 Baldi N , Russo VA, Lenti V. Relation between plasma levels and efficacy of flecainide and propafenone for treatment of atrial fibrillation of recent onset. New Trends Arrhythmias . 1993 ; 9 : 899 –906 234 Stambler BS , Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation . 1997 ; 96 : 4298 –4306 235 Guo GB , Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol . 1996 ; 27 : 1083 –1089 236 Volgman AS , Carberry PA, Stambler B. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol . 1998 ; 31 : 1414 –1419 237 Vos MA , Golitsyn SR, Stangl K. Superiority of ibutilide (a new class III agent) over dl-sotalol in converting atrial flutter and atrial fibrillation. Heart . 1998 ; 79 : 568 –575 238 Stambler BS , Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation . 1996 ; 94 : 1613 –1621 239 Ellenbogen KA , Stambler BS, Wood MA. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study [published erratum appears in J Am Coll Cardiol 1996; 28: 1082]. J Am Coll Cardiol . 1996 ; 28 : 130 –136 240 Boriani G , Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration. Chest . 1995 ; 108 : 355 –358 241 Boriani G , Biffi M, Capucci A. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: a randomized, controlled trial. Ann Intern Med . 1997 ; 126 : 621 –625 242 Fresco C , Proclemer A, Pavan A. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Clin Cardiol . 1996 ; 19 : 409 –412 243 Stroobandt R , Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol . 1997 ; 79 : 418 –423 244 Bellandi F , Cantini F, Pedone T, Palchetti R, Bamoshmoosh M, Dabizzi RP. Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Clin Cardiol . 1995 ; 18 : 631 –634 245 Bianconi L , Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol . 1996 ; 28 : 700 –706 246 Weiner P , Ganam R, Zidan F, Rabner M. Clinical course of recent-onset atrial fibrillation treated with oral propafenone. Chest . 1994 ; 105 : 1013 –1016 247 Di Benedetto S . Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol . 1997 ; 80 : 518 –519 248 Vita JA , Friedman PL, Cantillon C, Antman EM. Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol . 1989 ; 63 : 1275 –1278 249 Barroffio R , Tisi G, Guzzini F, Milvio E, Annoni P. A randomised study comparing digoxin and propafenone in the treatment of recent onset atrial fibrillation. Clin Drug Invest . 1995 ; 9 : 277 –283 250 Hohnloser SH , van de LA, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol . 1995 ; 26 : 852 –858 251 Halinen MO , Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol . 1995 ; 76 : 495 –498 252 Pilati G , Lenzi T, Trisolino G. Amiodarone versus quinidine for conversion of recent onset atrial fibrillation to sinus rhythm. Curr Ther Res . 1991 ; 49 : 140 –146 253 Sweany AE , Moncloa F, Vickers FF, Zupkis RV. Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clin Pharmacol Ther . 1985 ; 37 : 124 –127 254 Boudonas G , Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias. Acta Cardiol . 1995 ; 50 : 125 –134 255 Falk RH , Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med . 1987 ; 106 : 503 –506 256 Singh S , Saini RK, DiMarco J, Kluger J, Gold R, Chen YW. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol . 1991 ; 68 : 1227 –1230 257 Jordaens L . Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J . 1997 ; 18 : 643 –648 258 Eur Heart J . 1997 ; 18 : 649 –654 259 Madrid AH , Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J . 1993 ; 14 : 1127 –1131 260 Sung RJ , Tan HL, Karagounis L. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J . 1995 ; 129 : 739 –748 261 Singh S , Zoble RG, Yellen L. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation . 2000 ; 102 : 2385 –2390 262 Vardas PE , Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest . 2000 ; 117 : 1538 –1545 263 Hou CJ , Chang-Sing P, Flynn E. Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators. Circulation . 1995 ; 92 : 2558 –2564 264 Ewy GA . The optimal technique for electrical cardioversion of atrial fibrillation. Clin Cardiol . 1994 ; 17 : 79 –84 265 Dalzell GW , Cunningham SR, Anderson J, Adgey AA. Electrode pad size, transthoracic impedance and success of external ventricular defibrillation. Am J Cardiol . 1989 ; 64 : 741 –744 266 Connell PN , Ewy GA, Dahl CF, Ewy MD. Transthoracic impedance to defibrillator discharge: effect of electrode size and electrode-chest wall interface. J Electrocardiol . 1973 ; 6 : 313 –M 267 Kerber RE , Jensen SR, Grayzel J, Kennedy J, Hoyt R. Elective cardioversion: influence of paddle-electrode location and size on success rates and energy requirements. N Engl J Med . 1981 ; 305 : 658 –662 268 Mittal S , Ayati S, Stein KM. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation . 2000 ; 101 : 1282 –1287 269 Lown B , Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. JAMA . 1962 ; 182 : 548 –555 270 Lown B , Perlroth MG, Kaidbey S, Abe T, Harken DE. Cardioversion of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med . 1963 ; 269 : 325 –331 271 Kerber RE , Martins JB, Kienzle MG. Energy, current, and success in defibrillation and cardioversion: clinical studies using an automated impedance-based method of energy adjustment. Circulation . 1988 ; 77 : 1038 –1046 272 Crampton R . Accepted, controversial, and speculative aspects of ventricular defibrillation. Prog Cardiovasc Dis . 1980 ; 23 : 167 –186 273 Botto GL , Politi A, Bonini W, Broffoni T, Bonatti R. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart . 1999 ; 82 : 726 –730 274 Lesser MF . Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias. Am J Cardiol . 1990 ; 66 : 1267 –1268 275 Dahl CF , Ewy GA, Warner ED, Thomas ED. Myocardial necrosis from direct current countershock: effect of paddle electrode size and time interval between discharges. Circulation . 1974 ; 50 : 956 –961 276 Joglar JA , Hamdan MH, Ramaswamy K. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol . 2000 ; 86 : 348 –350 277 Van Gelder IC , Crijns HJ, van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol . 1991 ; 68 : 41 –46 278 Sodermark T , Jonsson B, Olsson A. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: a multicentre study from Stockholm. Br Heart J . 1975 ; 37 : 486 –492 279 Lundstrom T , Ryden L. Chronic atrial fibrillation: long-term results of direct current conversion. Acta Med Scand . 1988 ; 223 : 53 –59 280 Cramer G . Early and late results of conversion of atrial fibrillation with quinidine: a clinical and hemodynamic study. Acta Med Scand Suppl . 1968 ; 490 : 5 –102 281 Levy S , Lacombe P, Cointe R, Bru P. High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol . 1988 ; 12 : 514 –518 282 Levy S , Lauribe P, Dolla E. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation . 1992 ; 86 : 1415 –1420 283 Murgatroyd FD , Slade AK, Sopher SM, Rowland E, Ward DE, Camm AJ. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol . 1995 ; 25 : 1347 –1353 284 Alt E , Schmitt C, Ammer R. Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol . 1994 ; 17 : 1067 –1078 285 Levy S , Ricard P, Lau CP. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol . 1997 ; 29 : 750 –755 286 Levy S , Ricard P, Gueunoun M. Low-energy cardioversion of spontaneous atrial fibrillation: immediate and long-term results. Circulation . 1997 ; 96 : 253 –259 287 Schmitt C , Alt E, Plewan A. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol . 1996 ; 28 : 994 –999 288 Levine PA . Effect of cardioversion and defibrillation on implanted cardiac pacemakers. Barold SS. Modern Cardiac Pacing. Mount Kisco: Futura Publ; 1985. p. 875–876 289 Pollak A , Falk RH. The use of pacemakers in atrial fibrillation. Falk RH, Podrid PJ. Atrial Fibrillation. New York: Raven Press; 1992. p. 345–347 290 Prakash A , Saksena S, Mathew P, Krol RB. Internal atrial defibrillation: effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers. Pacing Clin Electrophysiol . 1997 ; 20 : 2434 –2441 291 Bjerkelund CJ , Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol . 1969 ; 23 : 208 –216 292 Arnold AZ , Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol . 1992 ; 19 : 851 –855 293 Rabbino MD , Likoff W, Dreifus LS. Complications and limitations of direct current countershock. JAMA . 1964 ; 190 : 417 –420 294 Lown B , Kleiger R, Williams J. Cardioversion and digitalis drugs: changed threshold to electric shock in digitalized animals. Circ Res . 1965 ; 17 : 519 –531 295 Aberg H , Cullhed I. Direct current countershock complications. Acta Med Scand . 1968 ; 183 : 415 –421 296 Ditchey RV , Karliner JS. Safety of electrical cardioversion in patients without digitalis toxicity. Ann Intern Med . 1981 ; 95 : 676 –679 297 Mancini GB , Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J . 1982 ; 104 : 617 –621 298 Lipkin DP , Frenneaux M, Stewart R, Joshi J, Lowe T, McKenna WJ. Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J . 1988 ; 59 : 572 –577 299 Patton JN , Allen JD, Pantridge JF. The effects of shock energy, propranolol, and verapamil on cardiac damage caused by transthoracic countershock. Circulation . 1984 ; 69 : 357 –368 300 Van Gelder IC , Crijns HJ, Van der LA, van Gilst WH, Lie KI. Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. Am Heart J . 1991 ; 121 : 51 –56 301 Ehsani A , Ewy GA, Sobel BE. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity. Am J Cardiol . 1976 ; 37 : 12 –18 302 Lund M , French JK, Johnson RN, Williams BF, White HD. Serum troponins T and I after elective cardioversion. Eur Heart J . 2000 ; 21 : 245 –253 303 Kerr CR , Talajic M, Connolly SJ. Recurrence of atrial fibrillation following its initial diagnosis: follow-up of the Canadian Registry of Atrial Fibrillation (Abstr). Circulation . 1999 ; 100 : I-286 304 Van Gelder IC , Crijns HJ, Tieleman RG. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med . 1996 ; 156 : 2585 –2592 305 Hohnloser SH , Kuck KH. Atrial fibrillation: maintaining sinus rhythm versus ventricular rate control: the PIAF trial: Pharmacological Intervention in Atrial Fibrillation. J Cardiovasc Electrophysiol . 1998 ; 9 : S121 –6 306 Deedwania PC , Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation . 1998 ; 98 : 2574 –2579 307 Tuinenburg AE , Van Gelder IC, Van Den Berg MP, Brugemann J, De Kam PJ, Crijns HJ. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart . 1999 ; 82 : 486 –493 308 Vaughan Williams EM . A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol . 1984 ; 24 : 129 –147 309 Tieleman RG , Van Gelder IC, Crijns HJ. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol . 1998 ; 31 : 167 –173 310 De Simone A , Stabile G, Vitale DF. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol . 1999 ; 34 : 810 –814 311 Anderson JL , Gilbert EM, Alpert BL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation . 1989 ; 80 : 1557 –1570 312 Clementy J , Dulhoste MN, Laiter C, Denjoy I, Dos SP. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol . 1992 ; 70 : 44A-9A 313 Suttorp MJ , Kingma JH, Koomen EM, van 't HA, Tijssen JG, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol . 1993 ; 71 : 710 –713 314 Prystowsky EN . Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol . 2000 ; 85 : 3 –11 315 Vorperian VR , Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol . 1997 ; 30 : 791 –798 316 Roy D , Talajic M, Dorian P. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med . 2000 ; 342 : 913 –920 317 Kochiadakis GE , Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart . 2000 ; 84 : 251 –257 318 Chun SH , Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol . 1995 ; 76 : 47 –50 319 Horowitz LN , Spielman SR, Greenspan AM. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol . 1985 ; 6 : 1402 –1407 320 Tuzcu EM , Gilbo J, Masterson M, Maloney JD. The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve Clin J Med . 1989 ; 56 : 238 –242 322 Vitolo E , Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol . 1981 ; 36 : 431 –444 323 Gosselink AT , Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA . 1992 ; 267 : 3289 –3293 324 Gold RL , Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol . 1986 ; 57 : 124 –127 325 Blevins RD , Kerin NZ, Benaderet D. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med . 1987 ; 147 : 1401 –1404 326 Brodsky MA , Allen BJ, Walker CJ III, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol . 1987 ; 60 : 572 –575 327 Steeds RP , Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart . 1999 ; 82 : 170 –175 328 Kuhlkamp V , Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol . 2000 ; 36 : 139 –146 329 Crijns HJ , Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. Cardiovasc Drugs Ther . 1996 ; 10 : 145 –152 330 Nakazawa H , Lythall DA, Noh J. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J . 2000 ; 21 : 327 –333 331 Hartel G , Louhija A, Konttinen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther . 1974 ; 15 : 551 –555 332 Karlson BW , Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation: a placebo-controlled one-year follow-up study. Eur Heart J . 1988 ; 9 : 284 –290 333 Lloyd EA , Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation: a double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J . 1984 ; 65 : 367 –369 334 Greenbaum RA , Campbell TJ, Channer KS. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: the EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study (Abstr). Circulation . 1998 ; 98 : I-1633 335 Pietersen AH , Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Am J Cardiol . 1991 ; 67 : 713 –717 336 Naccarelli GV , Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol . 1996 ; 77 : 53A –9A 337 Van Wijk LM , den Heijer P, Crijns HJ, van Gilst WH, Lie KI. Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol . 1989 ; 13 : 32 –36 338 Sonnhag C , Kallryd A, Nylander E, Ryden L. Long-term efficacy of flecainide in paroxysmal atrial fibrillation. Acta Med Scand . 1988 ; 224 : 563 –569 339 Van Gelder IC , Crijns HJ, van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol . 1989 ; 64 : 1317 –1321 340 Geller JC , Geller M, Carlson MD, Waldo AL. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Cardiol . 2001 ; 87 : 172 –177 341 Circulation . 1995 ; 92 : 2550 –2557 342 Connolly SJ , Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol . 1989 ; 63 : 817 –819 343 Lee SH , Chen SA, Chiang CE. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med . 1996 ; 239 : 253 –260 344 Reimold SC , Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol . 1993 ; 71 : 558 –563 345 Porterfield JG , Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol . 1989 ; 63 : 114 –116 346 Kerr CR , Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol . 1988 ; 61 : 914 –916 347 Hammill SC , Wood DL, Gersh BJ, Osborn MJ, Holmes DR Jr. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol . 1988 ; 61 : 473 –474 348 Antman EM , Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter [published erratum appears in J Am Coll Cardiol 1989; 13: 264]. J Am Coll Cardiol . 1988 ; 12 : 1005 –1011 349 Antman EM , Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol . 1990 ; 15 : 698 –707 350 Lee SH , Chen SA, Tai CT. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol . 1997 ; 79 : 905 –908 351 Coplen SE , Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials [published erratum appears in Circulation 1991; 83: 714]. Circulation . 1990 ; 82 : 1106 –1116 352 Carlsson J , Tebbe U, Rox J. Cardioversion of atrial fibrillation in the elderly. Am J Cardiol . 1996 ; 78 : 1380 –1384 353 Juul-Moller S , Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation . 1990 ; 82 : 1932 –1939 354 Hall JI , Wood DR. Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine. Br Heart J . 1968 ; 30 : 84 –90 355 Radford MD , Evans DW. Long-term results of DC reversion of atrial fibrillation. Br Heart J . 1968 ; 30 : 91 –96 356 Byrne-Quinn E , Wing AJ. Maintenance of sinus rhythm after DC reversion of atrial fibrillation: a double-blind controlled trial of long-acting quinidine bisulphate. Br Heart J . 1970 ; 32 : 370 –376 357 Hartel G , Louhija A, Konttinen A, Halonen PI. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J . 1970 ; 32 : 57 –60 358 Gunning JF , Kristinsson A, Miller G, Saunders K. Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine. Br Heart J . 1970 ; 32 : 462 –466 359 Hillestad L , Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: a controlled clinical study. Br Heart J . 1971 ; 33 : 518 –521 360 Boissel JP , Wolf E, Gillet J. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J . 1981 ; 2 : 49 –55 361 Rasmussen K , Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation: a controlled clinical trial. Acta Med Scand Suppl . 1981 ; 645 : 23 –28 362 Benditt DG , Williams JH, Jin J. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol . 1999 ; 84 : 270 –277 363 Wanless RS , Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J . 1997 ; 133 : 441 –446 364 Kalusche D , Stockinger J, Betz P, Roskamm H. Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation: conversion and 12-month follow-up: a randomized comparison [in German]. Z Kardiol . 1994 ; 83 : 109 –116 365 Simons GR , Eisenstein EL, Shaw LJ, Mark DB, Pritchett EL. Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol . 1997 ; 80 : 1551 –1557 366 Goethals P , Debruyne P, Saffarian M. Drug-induced Brugada syndrome. Acta Cardiol . 1998 ; 53 : 157 –160 367 Matana A , Goldner V, Stanic K, Mavric Z, Zaputovic L, Matana Z. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. Pacing Clin Electrophysiol . 2000 ; 23 : 416 –418 368 Feld GK . Atrial fibrillation: is there a safe and highly effective pharmacological treatment? Circulation . 1990 ; 82 : 2248 –2250 369 London F , Howell M. Atrial flutter: 1 to 1 conduction during treatment with quinidine and digitalis. Am Heart J . 1954 ; 48 : 152 –156 370 Leitch JW , Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern [published erratum appears in Circulation 1991; 83: 1124]. Circulation . 1990 ; 82 : 1718 –1723 371 Robertson CE , Miller HC. Extreme tachycardia complicating the use of disopyramide in atrial flutter. Br Heart J . 1980 ; 44 : 602 –603 372 Crijns HJ , Van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol . 1988 ; 62 : 1303 –1306 373 Timmermans C , Rodriguez LM, Ayers GM, Lambert H, Smeets J, Wellens HJ. Effect of electrode length on atrial defibrillation thresholds. J Cardiovasc Electrophysiol . 1998 ; 9 : 582 –587 374 Rossi M , Lown B. The use of quinidine in cardioversion. Am J Cardiol . 1967 ; 19 : 234 –238 375 Timmermans C , Rodriguez LM, Smeets JL, Wellens HJ. Immediate reinitiation of atrial fibrillation following internal atrial defibrillation. J Cardiovasc Electrophysiol . 1998 ; 9 : 122 –128 376 Van Gelder IC , Crijns HJ, van Gilst WH, De Langen CD, Van Wijk LM, Lie KI. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol . 1989 ; 63 : 112 –114 377 Oral H , Souza JJ, Michaud GF. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med . 1999 ; 340 : 1849 –1854 378 Li H , Natale A, Tomassoni G. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol . 1999 ; 84 : 1096 –1098 379 Van Noord T , Van Gelder IC, Schoonderwoerd BA, Crijns HJ. Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm on amiodarone. Am J Cardiol . 2000 ; 86 : 1384 –1385 380 Frick M , Ostergren J, Rosenqvist M. Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. Am J Cardiol . 1999 ; 84 : 104 –108 381 Singh SN , Fletcher RD, Fisher SG. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med . 1995 ; 333 : 77 –82 382 Julian DG , Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet . 1982 ; 1 : 1142 –1147 383 Julian DG , Camm AJ, Frangin G. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators [published errata appear in Lancet 1997; 349: 1180 and 1997; 349: 1776]. Lancet . 1997 ; 349 : 667 –674 384 Cairns JA , Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published erratum appears in Lancet 1997; 349: 1776]. Lancet . 1997 ; 349 : 675 –682 385 Hochman JS , Brooks MM, Morris. Prognostic significance of left ventricular aneurysm in the Cardiac Arrhythmia Suppression Trial (CAST) population. Am Heart J . 1994 ; 127 : 824 –832 386 Jackman WM , Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis . 1988 ; 31 : 115 –172 387 Ben David J , Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol . 1992 ; 20 : 1576 –1584 388 Van Gelder IC , Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol . 1999 ; 84 : 147R –51R 389 Cox JL , Schuessler RB, D'Agostino HJ Jr. The surgical treatment of atrial fibrillation, III: development of a definitive surgical procedure. J Thorac Cardiovasc Surg . 1991 ; 101 : 569 –583 390 Hioki M , Ikeshita M, Iedokoro Y. Successful combined operation for mitral stenosis and atrial fibrillation. Ann Thorac Surg . 1993 ; 55 : 776 –778 391 Nitta T , Lee R, Schuessler RB, Boineau JP, Cox JL. Radial approach: a new concept in surgical treatment for atrial fibrillation, I: concept, anatomic and physiologic bases and development of a procedure. Ann Thorac Surg . 1999 ; 67 : 27 –35 392 Melo J , Adragao P, Neves J. Surgery for atrial fibrillation using radiofrequency catheter ablation: assessment of results at one year. Eur J Cardiothorac Surg . 1999 ; 15 : 851 –854 393 Jais P , Shah DC, Takahashi A, Hocini M, Haissaguerre M, Clementy J. Long-term follow-up after right atrial radiofrequency catheter treatment of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol . 1998 ; 21 : 2533 –2538 394 Calkins H , Hall J, Ellenbogen K. A new system for catheter ablation of atrial fibrillation. Am J Cardiol . 1999 ; 83 : 227D –36D 395 Pappone C , Oreto G, Lamberti F. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation . 1999 ; 100 : 1203 –1208 396 Chen SA , Tai CT, Tsai CF, Hsieh MH, Ding YA, Chang MS. Radiofrequency catheter ablation of atrial fibrillation initiated by pulmonary vein ectopic beats. J Cardiovasc Electrophysiol . 2000 ; 11 : 218 –227 397 Haissaguerre M , Jais P, Shah DC. Catheter ablation of chronic atrial fibrillation targeting the reinitiating triggers. J Cardiovasc Electrophysiol . 2000 ; 11 : 2 –10 398 Haissaguerre M , Jais P, Shah DC. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation . 2000 ; 101 : 1409 –1417 399 Wellens HJ . Pulmonary vein ablation in atrial fibrillation: hype or hope? Circulation . 2000 ; 102 : 2562 –2564 400 Natale A , Newby KH, Pisano E. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol . 2000 ; 35 : 1898 –1904 401 Andersen HR , Nielsen JC, Thomsen PE. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet . 1997 ; 350 : 1210 –1216 402 Gillis AM , Wyse DG, Connolly SJ. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation. Circulation . 1999 ; 99 : 2553 –2558 403 Delfaut P , Saksena S, Prakash A, Krol RB. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol . 1998 ; 32 : 1900 –1908 406 Fitts SM , Hill MR, Mehra R. Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. J Interv Card Electrophysiol . 1998 ; 2 : 139 –144 407 Ayers GM , Alferness CA, Ilina M. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation . 1994 ; 89 : 413 –422 408 Levy S , Rodriguez LM, Camm J. Number, duration and frequency of nontreated atrial fibrillation episodes observed during the metrix automatic implantable defibrillator trial (Abstr). PACE . 1998 ; 21 : 811 409 Chorro FJ , Kirchhof CJ, Brugada J, Allessie MA. Ventricular response during irregular atrial pacing and atrial fibrillation. Am J Physiol . 1990 ; 259 : H1015 –21 410 Rawles JM . What is meant by a ‘controlled’ ventricular rate in atrial fibrillation? Br Heart J . 1990 ; 63 : 157 –161 411 Resnekov L , McDonald L. Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise. Br Heart J . 1971 ; 33 : 339 –350 412 Atwood JE , Myers J, Sandhu S. Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation. Am J Cardiol . 1989 ; 63 : 45 –48 413 Stein KM , Borer JS, Hochreiter C, Devereux RB, Kligfield P. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. Am J Cardiol . 1994 ; 74 : 906 –911 414 Frey B , Heinz G, Binder T. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. Am Heart J . 1995 ; 129 : 58 –65 415 Coumel P , Thomas O, Leenhardt A. Drug therapy for prevention of atrial fibrillation. Am J Cardiol . 1996 ; 77 : 3A –9A 416 Roberts SA , Diaz C, Nolan PE. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol . 1993 ; 72 : 567 –573 417 Lemery R , Brugada P, Cheriex E, Wellens HJ. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol . 1987 ; 60 : 1406 –1408 418 Rawles JM , Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J . 1990 ; 63 : 225 –227 419 Farshi R , Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol . 1999 ; 33 : 304 –310 420 Hays JV , Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med . 1994 ; 24 : 61 –64 421 Ellenbogen KA , Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol . 1991 ; 18 : 891 –897 422 Rinkenberger RL , Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation . 1980 ; 62 : 996 –1010 423 McGovern B , Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med . 1986 ; 104 : 791 –794 424 Gulamhusein S , Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J . 1983 ; 106 : 145 –147 425 Balser JR , Martinez EA, Winters BD. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology . 1998 ; 89 : 1052 –1059 426 Clemo HF , Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol . 1998 ; 81 : 594 –598 427 Segal JB , McNamara RL, Miller MR. The evidence regarding the drugs used for ventricular rate control. J Fam Pract . 2000 ; 49 : 47 –59 428 Anderson JL , Prystowsky EN. Sotalol: an important new antiarrhythmic. Am Heart J . 1999 ; 137 : 388 –409 429 Lewis RV , McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol . 1989 ; 13 : 1 –6 430 Circulation . 1995 ; 92 : 2764 –2784 431 Blumgart H . The reaction to exercise of the heart affected by auricular fibrillation. Heart . 1924 ; 11 : 49 –56 432 Scardi S , Humar F, Pandullo C, Poletti A. Oral clonidine for heart rate control in chronic atrial fibrillation (Letter). Lancet . 1993 ; 341 : 1211 –1212 433 Wittkampf FH , de Jongste MJ, Lie HI, Meijler FL. Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation. J Am Coll Cardiol . 1988 ; 11 : 539 –545 434 Williamson BD , Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation [published erratum appears in N Engl J Med 1995; 332: 479]. N Engl J Med . 1994 ; 331 : 910 –917 435 Feld GK , Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation . 1994 ; 90 : 2299 –2307 436 Evans GT Jr , Scheinman MM, Bardy G. Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction: results of a prospective, international, multicenter study. Circulation . 1991 ; 84 : 1924 –1937 437 Hart RG , Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol . 2000 ; 35 : 183 –187 438 Lancet . 1996 ; 348 : 633 –638 439 Lancet . 1993 ; 342 : 1255 –1262 440 Moulton AW , Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med . 1991 ; 91 : 156 –161 441 J Stroke Cerebrovasc Dis . 1995 ; 5 : 147 –157 442 Boysen G , Nyboe J, Appleyard M. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke . 1988 ; 19 : 1345 –1353 443 Landefeld CS , Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med . 1989 ; 87 : 144 –152 444 Beyth RJ , Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med . 2000 ; 133 : 687 –695 445 Hurley DM , Hunter AN, Hewett MJ, Stockigt JR. Atrial fibrillation and arterial embolism in hyperthyroidism. Aust NZJ Med . 1981 ; 11 : 391 –393 446 Yuen RW , Gutteridge DH, Thompson PL, Robinson JS. Embolism in thyrotoxic atrial fibrillation. Med J Aust . 1979 ; 1 : 630 –631 447 Staffurth JS , Gibberd MC, Fui SN. Arterial embolism in thyrotoxicosis with atrial fibrillation. BMJ . 1977 ; 2 : 688 –690 448 Bar-Sela S , Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med . 1981 ; 141 : 1191 –1192 449 Petersen P , Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke . 1988 ; 19 : 15 –18 450 Petersen P . Thromboembolic complications in atrial fibrillation. Stroke . 1990 ; 21 : 4 –13 451 Savage DD , Seides SF, Maron BJ, Myers DJ, Epstein SE. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation . 1979 ; 59 : 866 –875 452 Robinson K , Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol . 1990 ; 15 : 1279 –1285 453 Russell JW , Biller J, Hajduczok ZD, Jones MP, Kerber RE, Adams HP Jr. Ischemic cerebrovascular complications and risk factors in idiopathic hypertrophic subaortic stenosis. Stroke . 1991 ; 22 : 1143 –1147 454 Shigematsu Y , Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J . 1995 ; 59 : 329 –336 455 Higashikawa M , Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J . 1997 ; 61 : 673 –681 456 N Engl J Med . 1990 ; 323 : 1505 –1511 457 JAMA . 1998 ; 279 : 1273 –1277 458 Ann Intern Med . 1998 ; 128 : 639 –647 459 Fatkin D , Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for ‘atrial stunning’ as a mechanism of thromboembolic complications. J Am Coll Cardiol . 1994 ; 23 : 307 –316 460 Hart RG , Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med . 1999 ; 131 : 492 –501 461 Hellemons BS , Langenberg M, Lodder J. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ . 1999 ; 319 : 958 –964 462 Laupacis A , Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest . 1998 ; 114 : 579S –89S 463 Pearce LA , Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med . 2000 ; 109 : 45 –51 464 Singer DE . Patients with atrial fibrillation at low risk of stroke (Letter). JAMA . 1998 ; 280 : 882 –883 465 Howitt A , Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ . 1999 ; 318 : 1324 –1327 466 Wood KA , Eisenberg SJ, Kalman JM. Risk of thromboembolism in chronic atrial flutter. Am J Cardiol . 1997 ; 79 : 1043 –1047 467 Biblo LA , Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am J Cardiol . 2001 ; 87 : 346 –349 468 Petersen P , Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet . 1989 ; 1 : 175 –179 469 Ezekowitz MD , Bridgers SL, James KE. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published erratum appears in N Engl J Med 1993; 328: 148]. N Engl J Med . 1992 ; 327 : 1406 –1412 470 Arch Intern Med . 1996 ; 156 : 409 –416 471 Gorter JW . Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology . 1999 ; 53 : 1319 –1327 472 Hylek EM , Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med . 1994 ; 120 : 897 –902 473 Fihn SD , Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med . 1996 ; 124 : 970 –979 474 Sudlow M , Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet . 1998 ; 352 : 1167 –1171 475 Hylek EM , Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med . 1996 ; 335 : 540 –546 476 N Engl J Med . 1995 ; 333 : 5 –10 477 Hart RG . Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation (Letter). Ann Intern Med . 1998 ; 128 : 408 478 Minematsu K , Yasaka M, Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a prospective, randomized, multicenter trial (Abstr). Stroke . 1999 ; 30 : 241 479 Stein PD , Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest . 2001 ; 119 : 220S –7S 480 Bonow RO , Carabello B, de LA Jr. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation . 1998 ; 98 : 1949 –1984 481 Hirsh J , Warkentin TE, Shaughnessy SG. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest . 2001 ; 119 : 64S –94S 482 Warkentin TE , Levine MN, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995 ; 332 : 1330 –1335 483 Murray RD , Deitcher SR, Shah A. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr . 2001 ; 14 : 200 –208 484 Arch Intern Med . 1997 ; 157 : 1237 –1240 485 Munger TM , Packer DL, Hammill SC. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation . 1993 ; 87 : 866 –873 486 Hart RG , Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis . 1999 ; 9 : 215 –217 487 Gullov AL , Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study: Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med . 1999 ; 159 : 1322 –1328 488 Lancet . 1994 ; 343 : 687 –691 489 Connolly SJ , Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol . 1991 ; 18 : 349 –355 490 Morocutti C , Amabile G, Fattapposta F. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke . 1997 ; 28 : 1015 –1021 491 Pengo V , Zasso A, Barbero F. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol . 1998 ; 82 : 433 –437 492 Harenberg J , Weuster B, Pfitzer M. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost . 1993 ; 19 : 116 –121 493 Posada IS , Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J . 1999 ; 138 : 137 –143 494 Stroke . 1990 ; 21 : 1122 –1130 495 Naccarelli GV , Dell'Orfano JT, Wolbrette DL, Patel HM, Luck JC. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol . 2000 ; 85 : 36D –45D 496 Moreyra E , Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J . 1995 ; 129 : 71 –75 497 Van Gelder IC , Crijns HJ, Blanksma PK. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol . 1993 ; 72 : 560 –566 498 Petersen P , Kastrup J, Videbaek R, Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. J Cereb Blood Flow Metab . 1989 ; 9 : 422 –425 499 Antonielli E , Pizzuti A, Bassignana A. Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. Am J Cardiol . 1999 ; 84 : 1092 –1010 500 Falcone RA , Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol . 1996 ; 78 : 435 –439 501 Bellotti P , Spirito P, Lupi G, Vecchio C. Left atrial appendage function assessed by transesophageal echocardiography before and on the day after elective cardioversion for nonvalvular atrial fibrillation. Am J Cardiol . 1998 ; 81 : 1199 –1202 502 Harjai K , Mobarek S, Abi-Samra F. Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion. Am J Cardiol . 1998 ; 81 : 1125 –1129 503 Sparks PB , Jayaprakash S, Vohra JK. Left atrial ‘stunning’ following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol . 1998 ; 32 : 468 –475 504 Manning WJ , Silverman DI, Katz SE. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol . 1995 ; 75 : 624 –626 505 Grimm RA , Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage ‘stunning’ after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J . 1995 ; 130 : 174 –176 506 Berger M , Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol . 1998 ; 82 : 1545 –1547 507 Mehta D , Baruch L. Thromboembolism following cardioversion of ‘common’ atrial flutter: risk factors and limitations of transesophageal echocardiography. Chest . 1996 ; 110 : 1001 –1003 508 Irani WN , Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: a prospective study using transesophageal echocardiography. Circulation . 1997 ; 95 : 962 –966 509 Lazzeroni E , Picano E, Morozzi L. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Circulation . 1997 ; 96 : 4268 –4272 510 Soria R , Guize L, Chretien JM. The natural history of 270 cases of Wolff-Parkinson-White syndrome in a survey of the general population [in French]. Arch Mal Coeur Vaiss . 1989 ; 82 : 331 –336 511 Creswell LL , Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg . 1993 ; 56 : 539 –549 512 Andrews TC , Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation . 1991 ; 84 : III-236 –III-244 513 Stebbins D , Igidbashian L, Goldman SM. Clinical outcome of patients who develop atrial fibrillation after coronary artery bypass graft surgery (Abstr). PACE . 1995 ; 18 : 798 514 Dixon FE , Genton E, Vacek JL, Moore CB, Landry J. Factors predisposing to supraventricular tachyarrhythmias after coronary artery bypass grafting. Am J Cardiol . 1986 ; 58 : 476 –478 515 Leitch JW , Thomson D, Baird DK, Harris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg . 1990 ; 100 : 338 –342 516 Fuller JA , Adams GG, Buxton B. Atrial fibrillation after coronary artery bypass grafting: is it a disorder of the elderly? J Thorac Cardiovasc Surg . 1989 ; 97 : 821 –825 517 Aranki SF , Shaw DP, Adams DH. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation . 1996 ; 94 : 390 –397 518 Caretta Q , Mercanti CA, De Nardo D. Ventricular conduction defects and atrial fibrillation after coronary artery bypass grafting: multivariate analysis of preoperative, intraoperative and postoperative variables. Eur Heart J . 1991 ; 12 : 1107 –1111 519 Falk RH . Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol . 1998 ; 82 : 10N –7N 520 Cox JL . A perspective of postoperative atrial fibrillation in cardiac operations (Editorial). Ann Thorac Surg . 1993 ; 56 : 405 –409 521 Page P , Hassanalizadeh H, Cardinal R. Transition between atrial fibrillation, unstable or sustained flutter, and sinus rhythm during procainamide injection or vagal stimulation in dogs with sterile pericarditis. Circulation . 1988 ; 78 : II-613 522 Matangi MF , Neutze JM, Graham KJ, Hill DG, Kerr AR, Barratt-Boyes BG. Arrhythmia prophylaxis after aorta-coronary bypass: the effect of minidose propranolol. J Thorac Cardiovasc Surg . 1985 ; 89 : 439 –443 523 Parikka H , Toivonen L, Heikkila L, Virtanen K, Jarvinen A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol . 1998 ; 31 : 67 –73 524 Gomes JA , Ip J, Santoni-Rugiu F. Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol . 1999 ; 34 : 334 –339 525 Daoud EG , Strickberger SA, Man KC. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med . 1997 ; 337 : 1785 –1791 526 Guarnieri T , Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol . 1999 ; 34 : 343 –347 527 Kowey PR , Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol . 1992 ; 69 : 963 –965 528 Podrid PJ . Prevention of postoperative atrial fibrillation: what is the best approach? J Am Coll Cardiol . 1999 ; 34 : 340 –342 529 Gold MR , O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol . 1996 ; 78 : 975 –979 530 Fan K , Lee KL, Chiu CS. Effects of biatrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery. Circulation . 2000 ; 102 : 755 –760 531 Chapman MJ , Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med . 1993 ; 19 : 48 –52 532 McAlister HF , Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg . 1990 ; 99 : 911 –918 533 Hjelms E . Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg . 1992 ; 26 : 193 –196 534 Gray RJ , Bateman TM, Czer LS, Conklin CM, Matloff JM. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol . 1985 ; 5 : 1451 –1456 535 VanderLugt JT , Mattioni T, Denker S. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation . 1999 ; 100 : 369 –375 536 Reed GL III , Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery: a case-control estimate of the risk from carotid bruits. N Engl J Med . 1988 ; 319 : 1246 –1250 537 Taylor GJ , Malik SA, Colliver JA. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol . 1987 ; 60 : 905 –907 538 Wells JL Jr , MacLean WA, James TN, Waldo AL. Characterization of atrial flutter: studies in man after open heart surgery using fixed atrial electrodes. Circulation . 1979 ; 60 : 665 –673 539 Pedersen OD , Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J . 1999 ; 20 : 748 –754 540 Crenshaw BS , Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol . 1997 ; 30 : 406 –413 541 Eldar M , Canetti M, Rotstein Z. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. Circulation . 1998 ; 97 : 965 –970 542 Ryan TJ , Antman EM, Brooks NH. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol . 1999 ; 34 : 890 –911 543 Goldberg RJ , Seeley D, Becker RC. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J . 1990 ; 119 : 996 –1001 544 Behar S , Zahavi Z, Goldbourt U, Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J . 1992 ; 13 : 45 –50 545 Flensted-Jensen E . Wolff-Parkinson-White syndrome: a long-term follow-up of 47 cases. Acta Med Scand . 1969 ; 186 : 65 –74 546 Zardini M , Yee R, Thakur RK, Klein GJ. Risk of sudden arrhythmic death in the Wolff-Parkinson-White syndrome: current perspectives. Pacing Clin Electrophysiol . 1994 ; 17 : 966 –975 547 Jackman WM , Wang XZ, Friday KJ. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med . 1991 ; 324 : 1605 –1611 548 Davidson E , Weinberger I, Rotenberg Z, Fuchs J, Agmon J. Atrial fibrillation: cause and time of onset. Arch Intern Med . 1989 ; 149 : 457 –459 549 Agner T , Almdal T, Thorsteinsson B, Agner E. A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull . 1984 ; 31 : 157 –159 550 Nakazawa HK , Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med . 1982 ; 72 : 903 –906 551 Clozel JP , Danchin N, Genton P, Thomas JL, Cherrier F. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism. Clin Pharmacol Ther . 1984 ; 36 : 64 –69 552 Hirsh J . Oral anticoagulant drugs. N Engl J Med . 1991 ; 324 : 1865 –1875 553 Bhanderi AK , Isher N. Cardiac arrhythmias and pregnancies. Gleicher N. Principles and Practice of Medical Therapy in Pregnancy. Stamford: Appleton & Lange; 1998. p. 975–987 554 Bryg RJ , Gordon PR, Kudesia VS, Bhatia RK. Effect of pregnancy on pressure gradient in mitral stenosis. Am J Cardiol . 1989 ; 63 : 384 –386 555 Whittemore R , Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol . 1982 ; 50 : 641 –651 556 Forfar JC , Miller HC, Toft AD. Occult thyrotoxicosis: a correctable cause of ‘idiopathic’ atrial fibrillation. Am J Cardiol . 1979 ; 44 : 9 –12 557 Page RL . Treatment of arrhythmias during pregnancy. Am Heart J . 1995 ; 130 : 871 –876 558 Cox JL , Gardner MJ. Cardiovascular drugs in pregnancy and lactation. Gleicher N, Gall SA, Sibai BM. Principles and Practice of Medical Therapy in Pregnancy. Stamford: Appleton & Lange; 1998. p. 911–926 559 Chow T , Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol . 1998 ; 82 : 58I –62I 560 Lownes HE , Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol . 1987 ; 157 : 446 –447 561 Wagner X , Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J . 1990 ; 119 : 700 –702 562 Ovadia M , Brito M, Hoyer GL, Marcus FI. Human experience with amiodarone in the embryonic period. Am J Cardiol . 1994 ; 73 : 316 –317 563 Magee LA , Downar E, Sermer M, Boulton BC, Allen LC, Koren G. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol . 1995 ; 172 : 1307 –1311 564 Foster CJ , Love HG. Amiodarone in pregnancy: case report and review of the literature. Int J Cardiol . 1988 ; 20 : 307 –316 565 Leung CY , Brodsky MA. Cardiac arrhythmias and pregnancy: diagnosis and management of maternal and fetal disease. Elkayam U, Gleicher N. Cardiac Problems in Pregnancy. New York: Wiley-Liss; 1998. p. 155–175 566 Ginsberg JS , Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest . 2001 ; 119 : 122S –31S 567 Stevenson RE , Burton OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA . 1980 ; 243 : 1549 –1551 568 Iturbe-Alessio I , Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med . 1986 ; 315 : 1390 –1393 569 Ginsberg JS , Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med . 1989 ; 149 : 2233 –2236 570 Elkayam UR . Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol . 1996 ; 27 : 1704 –1706 571 Anderson DR , Ginsberg JS, Brill-Edwards P, Demers C, Burrows RF, Hirsh J. The use of an indwelling Teflon catheter for subcutaneous heparin administration during pregnancy: a randomized crossover study. Arch Intern Med . 1993 ; 153 : 841 –844 572 Vitale N , De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol . 1999 ; 33 : 1637 –1641 573 Maron BJ , Olivotto I, Spirito P. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation . 2000 ; 102 : 858 –864 574 McKenna WJ , England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy, I: influence on prognosis. Br Heart J . 1981 ; 46 : 168 –172 575 Shih HT , Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest . 1988 ; 94 : 44 –48 576 Hudson LD , Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest . 1973 ; 63 : 661 –665 577 Fuso L , Incalzi RA, Pistelli R. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med . 1995 ; 98 : 272 –277 578 Payne RM . Management of arrhythmias in patients with severe lung disease. Clin Pulm Med . 1994 ; 1 : 232 –237 579 Andersen HR , Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet . 1994 ; 344 : 1523 –1528 580 Connolly SJ , Kerr CR, Gent M. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med . 2000 ; 342 : 1385 –1391 Article PDF first page preview Close This content is only available as a PDF. The European Society of Cardiology
TI - Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
JF - European Heart Journal
DO - 10.1053/euhj.2001.2983
DA - 2001-10-01
UR - https://www.deepdyve.com/lp/oxford-university-press/guidelines-for-the-management-of-patients-with-atrial-fibrillation-a-Ik61iv3D07
SP - 1852
VL - 22
IS - 20
DP - DeepDyve
ER -